Join the Nonalcoholic Fatty Liver Disease group to help and get support from people like you.
Nonalcoholic Fatty Liver Disease News
Related terms: Nonalcoholic Steatohepatitis, Idiopathic Fatty Liver, Steatosis, Steatohepatitis, Fatty Liver, NASH, NAFLD, MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic Dysfunction-Associated Steatotic Liver Disease Linked to Risk for Sudden Hearing Loss
FRIDAY, June 20, 2025 – Among older adults, metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with increased risk for sudden sensorineural hearing loss (SSNHL),...
Waist-to-Height Ratio Predicts Liver Steatosis and Fibrosis
WEDNESDAY, June 18, 2025 – Waist-to-height ratio (WHtR) outperforms body mass index (BMI) in detecting the risk for liver disease, according to a study published in the July issue of the Journal of ...
Diabetes Drug, Dapagliflozin, Effective For Fatty Liver Disease
FRIDAY, June 6, 2025 — A repurposed diabetes drug can be an effective tool against fatty liver disease, a new clinical trial has found. Dapagliflozin helped people reduce fat levels in their liver a...
Dapagliflozin Beneficial for Improving MASH Without Worsening Fibrosis
FRIDAY, June 6, 2025 – For patients with metabolic dysfunction-associated steatohepatitis (MASH), treatment with dapagliflozin is beneficial for improvement of MASH without worsening of fibrosis and...
Metabolic Dysfunction-Linked Steatotic Liver Disease Tied to Increased Preterm Birth Risk
TUESDAY, May 20, 2025 – Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnant women is a risk factor for preterm birth, according to a study published online May 9 in...
Study IDs Trends in 2015 to 2023 Mortality for Chronic Liver Disease
THURSDAY, May 8, 2025 – Distinct trends were seen in etiology-based mortality with chronic liver disease (CLD) before, during, and after the COVID-19 pandemic, according to a research letter...
Semaglutide Beneficial in Metabolic Dysfunction-Associated Steatohepatitis, Fibrosis
FRIDAY, May 2, 2025 – For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes, according to a study...
Ozempic Can Treat Fatty Liver Disease
THURSDAY, May 1, 2025 – The cutting-edge weight-loss drug Ozempic/Wegovy can stop and even reverse fatty liver disease, a new clinical trial has found. Nearly twice as many people taking semaglutide...
Blood Test Can Predict Fatty Liver Disease
FRIDAY, April 25, 2025 – Doctors can accurately predict a person’s risk of fatty liver disease as early as 16 years before symptoms develop, a new study says. A blood test looking for five specific p...
DDW: Certain Proteins Predict Metabolic Dysfunction-Associated Steatotic Liver Disease
FRIDAY, April 25, 2025 – Five proteins are significant predictors of metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study presented at the 2025 Digestive Disease...
'Broken' Sleep Could Be Hallmark of Obesity-Linked Liver Disease
THURSDAY, Dec. 5, 2024 – Fatty liver disease may contribute to fragmented sleep patterns, robbing already sick people of good rest, a new study finds. These folks woke up more often in the night,...
AI Algorithm Can ID Metabolic Dysfunction-Associated Steatotic Liver Disease
WEDNESDAY, Nov. 27, 2024 – An algorithm can identify individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) with about 88 percent accuracy using electronic medical record...
AI Helps Spot Liver Disease Early
MONDAY, Nov. 18, 2024 – AI can help doctors diagnose early cases of fatty liver disease, a new study says. An AI program trained to spot a leading type of the disease, called metabolic-associated...
Fatty Liver Disease Now Affects 4 in 10 U.S. Adults
WEDNESDAY, Nov. 13, 2024 – Obesity, alcohol use and other factors are driving up rates of fatty liver disease among American adults, new research warns. By 2018, federal data showed that 42% of...
GLP-1 RA Use Linked to Reduced Cirrhosis Risk in MASLD, Diabetes
TUESDAY, Sept. 17, 2024 – For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with...